Agios Pharmaceuticals Inc. had the near-commercial asset and Cstone Pharmaceuticals Co. Ltd. had the market intel and rapidly maturing R&D engine. Together, the companies represent a formidable team to advance ivosidenib (Tibsovo, AG-120) in China, including Hong Kong, Macau and Taiwan, as monotherapy or in combination efforts. The oral isocitrate dehydrogenase 1 mutant, or IDH1m, inhibitor is under priority review by the FDA with an Aug. 21 PDUFA date for the treatment of individuals with relapsed or refractory acute myeloid leukemia (r/r AML).